

POLICY Document for JOBEVNE

The overall objective of this policy is to support the appropriate and cost-effective use of the medication, specific to use of preferred medication options, and overall, clinically appropriate use. This document provides specific information to both sections of the overall policy.

Section 1: Preferred Product

- Policy information specific to preferred medications

Section 2: Clinical Criteria

- Policy information specific to the clinical appropriateness for the medication

Section 3: Oncology Clinical Policy

- Policy information specific to regimen review per NCCN Guidelines.

Section 1: Preferred Product

CAREFIRST: EXCEPTIONS CRITERIA BEVACIZUMAB-ONCOLOGY PRODUCTS

PREFERRED PRODUCTS: MVASI AND ZIRABEV

Client Requested: The intent of the criteria is to ensure that patients follow selection elements as established by CareFirst.

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the bevacizumab products specified in this policy when the requested drug will be used to treat cancer. Coverage for targeted product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with a targeted product.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Bevacizumab-Oncology Products

	Product(s)
Preferred*	<ul style="list-style-type: none"> • Mvasi (bevacizumab-awwb) • Zirabev (bevacizumab-bvzr)
Targeted	<ul style="list-style-type: none"> • Alymsys (bevacizumab-maly) • Avastin (bevacizumab) • Jobevne (bevacizumab-nwgd)

	• Vegzelma (bevacizumab-adcd)
--	--------------------------------------

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review

II. EXCEPTION CRITERIA

This program applies to members requesting treatment for cancer where the indication is FDA-approved for the preferred products.

Coverage for the targeted product is provided when member has a documented inadequate response, contraindication, or intolerable adverse event to both preferred products and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).

Section 2: Clinical Criteria

Specialty Guideline Management Avastin and Biosimilars

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Avastin	bevacizumab
Alymsys	bevacizumab-maly
Avzivi	bevacizumab-tnjn
Jobevne	bevacizumab-nwgd
Mvasi	bevacizumab-awwb
Vegzelma	bevacizumab-adcd
Zirabev	bevacizumab-bvzr

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications^{1-6,32}

Metastatic Colorectal Cancer (mCRC)

- Avastin, Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer.
- Avastin, Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab product-containing regimen.

First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Avastin, Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer.

Recurrent Glioblastoma (RGM)

Avastin, Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma or Zirabev, is indicated for the treatment of recurrent glioblastoma in adults.

Metastatic Renal Cell Carcinoma (mRCC)

Avastin, Alymsys, Avzivi, Mvasi, Vegzelma or Zirabev, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma.

Persistent, Recurrent, or Metastatic Cervical Cancer

Avastin, Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

- Avastin, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with carboplatin and paclitaxel, followed by Avastin, Jobevne, Mvasi, Vegzelma or Zirabev as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
- Avastin, Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.
- Avastin, Jobevne, Mvasi, Vegzelma or Zirabev, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin, Jobevne, Mvasi, Vegzelma or Zirabev as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Hepatocellular Carcinoma

Avastin, in combination with atezolizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Compendial Uses⁷⁻³¹

- Central Nervous System (CNS) Cancers
 - Circumscribed glioma
 - Diffuse high grade and high grade gliomas
 - Glioblastoma
 - IDH mutant astrocytoma (WHO Grade 2, 3, or 4)
 - Oligodendroglioma (WHO Grade 2 or 3)
 - Intracranial and Spinal Ependymoma (excluding subependymoma)
 - Medulloblastoma
 - Primary Central Nervous System Lymphoma
 - Meningiomas
 - Limited and Extensive Brain Metastases
 - Metastatic Spine Tumors
 - Primary Spinal Cord Tumors
- Pleural Mesothelioma, Peritoneal Mesothelioma, Pericardial Mesothelioma, Tunica Vaginalis Testis Mesothelioma
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Soft Tissue Sarcoma
 - Angiosarcoma
 - Solitary Fibrous Tumor/Hemangiopericytoma
- Uterine Neoplasms/Endometrial Carcinoma
- Vulvar Carcinoma
- Vaginal Cancer
- Cervical Cancer
- Small Bowel Adenocarcinoma
- Ampullary Adenocarcinoma
- Appendiceal Adenocarcinoma
- Anal Adenocarcinoma
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Ophthalmic Disorders
 - Diabetic Macular Edema
 - Neovascular (wet) Age-Related Macular Degeneration
 - Macular Edema following Retinal Vein Occlusion
 - Proliferative Diabetic Retinopathy
 - Choroidal Neovascularization
 - Neovascular Glaucoma
 - Retinopathy of Prematurity
 - Polypoidal Choroidal Vasculopathy

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Ophthalmic Disorders^{8-26,30}

Authorization of 6 months may be granted for treatment of the following retinal disorders:

- Diabetic Macular Edema
- Neovascular (wet) Age-Related Macular Degeneration
- Macular Edema following Retinal Vein Occlusion
- Proliferative Diabetic Retinopathy
- Choroidal Neovascularization (including myopic choroidal neovascularization, angioid streaks, choroiditis [including choroiditis secondary to ocular histoplasmosis], idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma)
- Neovascular Glaucoma
- Retinopathy of Prematurity
- Polypoidal Choroidal Vasculopathy

Colorectal Cancer (CRC)^{1-8,27,28,29,32}

Authorization of 12 months may be granted for treatment of colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma.

Small Bowel Adenocarcinoma⁷

Authorization of 12 months may be granted for treatment of small bowel adenocarcinoma.

Ampullary Adenocarcinoma⁷

Authorization of 12 months may be granted for treatment of intestinal-type ampullary adenocarcinoma that is progressive, unresectable, or metastatic.

Non-Small Cell Lung Cancer (NSCLC)^{1-7,32}

Authorization of 12 months may be granted for treatment of recurrent, unresectable, advanced, or metastatic non-squamous NSCLC.

CNS Cancer^{1-7,32}

Authorization of 12 months may be granted for treatment of the following types of CNS cancer:

- Circumscribed glioma
- Diffuse high grade and high grade gliomas
- Glioblastoma
- IDH mutant astrocytoma (WHO Grade 2, 3 or 4)
- Oligodendroglioma (WHO Grade 2 or 3)
- Intracranial and Spinal Ependymoma (excludes subependymoma)
- Medulloblastoma



- Primary Central Nervous System Lymphoma
- Meningiomas
- Limited and Extensive Brain Metastases
- Metastatic Spine Tumors
- Primary Spinal Cord Tumors

Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer^{1-7,31}

Authorization of 12 months may be granted for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and malignant sex cord stromal tumors.

Uterine Neoplasms/Endometrial Carcinoma^{7,30}

Authorization of 12 months may be granted for treatment of progressive, persistent, recurrent, or metastatic uterine neoplasms or endometrial carcinoma.

Cervical Cancer^{1-7,32}

Authorization of 12 months may be granted for treatment of persistent, recurrent, or metastatic cervical cancer.

Vaginal Cancer⁷

Authorization of 12 months may be granted for treatment of recurrent or metastatic vaginal cancer.

Renal Cell Carcinoma^{1-7,32}

Authorization of 12 months may be granted for treatment of relapsed or stage IV renal cell carcinoma.

Soft Tissue Sarcoma^{7,31}

Authorization of 12 months may be granted for treatment of angiosarcoma, as single agent therapy.

Authorization of 12 months may be granted for treatment of solitary fibrous tumor or hemangiopericytoma, in combination with temozolomide.

Mesothelioma^{7,8}

Authorization of 12 months may be granted for treatment of pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma when any of the following criteria are met:

- As first-line therapy in combination with pemetrexed and either cisplatin or carboplatin, followed by single-agent maintenance bevacizumab
- As subsequent therapy in combination with pemetrexed and either cisplatin or carboplatin if immunotherapy was administered as first-line treatment



Authorization of 12 months may be granted for treatment of peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma when used in combination with atezolizumab as subsequent therapy.

Vulvar Carcinoma⁷

Authorization of 12 months may be granted for treatment of advanced, recurrent, or metastatic vulvar carcinoma, including squamous cell carcinoma and adenocarcinoma.

Hepatocellular Carcinoma^{1,7}

Authorization of 12 months may be granted for treatment of unresectable or extrahepatic/metastatic hepatocellular carcinoma, when the requested medication will be used as initial treatment in combination with atezolizumab.

Authorization of 12 months may be granted for adjuvant treatment of operable hepatocellular carcinoma, when the member is at a high risk of recurrence and the requested medication will be used in combination with atezolizumab.

Continuation of Therapy

Ophthalmic Disorders

For ophthalmic disorders, authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in coverage criteria section when the member has demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss).

All Other Indications

For all other indications, authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Section 3: Oncology Clinical Policy

PURPOSE

The purpose of this policy is to define the Novologix NCCN[®] Regimen Prior Authorization Program.

SCOPE

CareFirst Specialty Exceptions bevacizumab-Oncology C26636-D 10-2025.docx
Avastin and Biosimilars SGM 1891-A P2025a.docx
Novologix LLC_NCCN Oncology Clinical Policy_12.2025

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



This policy applies to clients who have implemented the Novologix NCCN® Program as a part of their medical and/or pharmacy prior authorization solution.

Program Description

The National Comprehensive Care Network® (NCCN®) is a not-for profit alliance of leading cancer centers devoted to patient care, research and education dedicated to improving the quality, effectiveness and efficiency of cancer care so patients can live better lives. It is comprised of oncology experts who convene regularly to establish the best treatments for patients.¹

NCCN develops resources to support stakeholders in the health care delivery system including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®) and the NCCN Chemotherapy Order Templates (NCCN Templates®).

The Guidelines offer broad, high-level, evidence-based recommendations for cancer management. The Compendium extracts the drug and biologic recommendations from the Guidelines detailing their use and level of evidence category. The Templates convert the drug regimens detailed in the Guidelines and Compendium into practical, standardized order sets for safe, clinical use.^{2,3}

NCCN Categories of Evidence and Consensus⁴

- **Category 1:** Based upon high-level evidence, there is uniform (defined as ≥85% panel support) NCCN consensus that the intervention is appropriate.
- **Category 2A:** Based upon lower-level evidence, there is uniform (≥85% panel support) NCCN consensus that the intervention is appropriate.
- **Category 2B:** Based upon lower-level evidence, there is NCCN consensus (50% to <85% panel support) that the intervention is appropriate.
- **Category 3:** Based upon any level of evidence, there is major NCCN disagreement (less than 50% panel support, or at least three institutions opposing the recommendation) that the intervention is appropriate.

Policy for Regimen Prior Authorization

Regimen prior authorization allows providers to submit a single request for all oncology drugs or biologics within an NCCN Template that require prior authorization. Regimen requests must be initiated through the provider portal. If submitted via phone or fax, each drug or biologic must be requested individually using drug-specific criteria.

Coverage is provided for a regimen request when all the following criteria are met. If all are not met, further review may be required:

1. The request is initiated through the provider portal.
2. The member is eligible for regimen review.
3. The request is for an oncology drug or biologic.
4. The requested regimen and indication align with an NCCN recommendation with a level of evidence category 1 or 2A.
5. The NCCN template is accepted by the provider without modification.

6. The indication is for a cancer type currently eligible for regimen review.
6. The indication is for a cancer type currently eligible for regimen review.
 1. Ampullary Adenocarcinoma
 2. Anal Carcinoma
 3. Appendiceal Neoplasms and Cancers
 4. Basal Cell Skin Cancer
 5. B-Cell Lymphomas
 6. Biliary Tract Cancers
 7. Bladder Cancer
 8. Bone Cancer
 9. Breast Cancer
 10. Castleman Disease
 11. Central Nervous System Cancers
 12. Cervical Cancer
 13. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
 14. Chronic Myeloid leukemia
 15. Colon Cancer
 16. Cutaneous Lymphomas
 17. Dermatofibrosarcoma Protuberans
 18. Esophageal Cancer
 19. Gastric Cancer
 20. Gastrointestinal Stromal Tumors
 21. Gestational Trophoblastic Neoplasms
 22. Hairy Cell Leukemia
 23. Head and Neck Cancers
 24. Hepatocellular Carcinoma
 25. Histiocytic Neoplasms
 26. Hodgkin Lymphoma
 27. Kaposi Sarcoma
 28. Kidney Cancer
 29. Melanoma: Cutaneous
 30. Melanoma: Uveal
 31. Merkel Cell Carcinoma
 32. Mesothelioma: Peritoneal
 33. Mesothelioma: Pleural
 34. Multiple Myeloma
 35. Myelodysplastic Syndromes
 36. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions
 37. Myeloproliferative Neoplasms
 38. Neuroendocrine and Adrenal Tumors
 39. Non-Small Cell Lung Cancer
 40. Occult Primary
 41. Ovarian Cancer
 42. Pancreatic Cancer
 43. Penile Cancer
 44. Prostate Cancer

45. Rectal Cancer
46. Small Bowel Adenocarcinoma
47. Small Cell Lung Cancer
48. Soft Tissue Sarcoma
49. Squamous Cell Skin Cancer
50. Systemic Light Chain Amyloidosis
51. Systemic Mastocytosis
52. T-Cell Lymphomas
53. Testicular Cancer
54. Thymomas and Thymic Carcinomas
55. Thyroid Carcinoma
56. Uterine Neoplasms
57. Vaginal Cancer
58. Vulvar Cancer
59. Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma
60. Wilms Tumor (Nephroblastoma)

Supportive Care: Myeloid Growth Factor Therapy

Granulocyte colony stimulating factors (G-CSFs) are recommended for primary prophylaxis based on the febrile neutropenia (FN) risk of the chemotherapy regimen. The level of FN risk varies by NCCN Template and is indicated at the top of each template. Regimens classified as high or intermediate risk of FN may include a G-CSF as part of the prior authorization

Dosage and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and evidence-based practice guidelines.

Duration of Approval

Authorizations may be granted for 12 months or as medically necessary, based on the member's condition and provider's clinical assessment.

Continuation of Therapy

To submit a request for continuation of therapy, a new regimen prior authorization review must be requested. If no specific template exists for the intended maintenance therapy, the selected template can be modified to include only the appropriate maintenance agents. The modified regimen request will be submitted for further review.

REFERENCES:

SECTION 1

1. Alymsys [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2022.
2. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; February 2024.
3. Jobevne [package insert]. Cambridge, MA: Biocon Biologics Inc.; April 2025.
4. Mvasi [package insert]. Thousand Oaks, CA: Amgen, Inc.; February 2023.
5. Vegzelma [package insert]. Jersey City, NJ; Celltrion USA, Inc. February 2023.

SECTION 2

1. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; September 2022.
2. Alysmsys [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; April 2022.
3. Avzivi [package insert]. Guangzhou, Guangdong Province, China: Bio-Thera Solutions, Ltd.; December 2023.
4. Mvasi [package insert]. Thousand Oaks, CA: Amgen Inc.; February 2023.
5. Zirabev [package insert]. New York, NY: Pfizer Inc.; August 2024.
6. Vegzelma [package insert]. Incheon, Republic of Korea: Celltrion, Inc.; February 2023.
7. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed November 11, 2024.
8. Micromedex Solutions [database online]. Truven Health Analytics, Greenwood Village, CO. Available at: <http://www.micromedexsolutions.com>. Accessed February 10, 2025.
9. Chan WM, Lai TY, Lui DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. *Br J Ophthalmol*. 2009;93(2):150-154.
10. Clinical Consult: CVS Caremark Clinical Programs Review. Focus on Age-Related Macular Degeneration Clinical Programs. April 2011.
11. Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration. *Eye*. 2010;24:203-213.
12. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2011;364(20):1897-1908.
13. Russo V, Barone A, Conte E, et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. *Retina*. 2009;29:511-5.
14. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. *Ophthalmology*. 2010;117:1078-1086.
15. Mirshahi A, Roohipour R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. *Eur J Ophthalmol*. 2008;18(2):263-269.
16. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. *J Glaucoma*. 2009;18(8):632-637.
17. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. *N Engl J Med*. 2011;364(7):603-615.
18. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>.
19. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp>.
20. American Academy of Ophthalmology Retinal/Vitreous Panel. Preferred Practice Pattern® Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; 2019. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp>.

21. VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy in primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2017. May;124(5):619-633.
22. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed November 12, 2024.
23. Yong M, Zhou M, Deng G. Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis. *BMC Ophthalmol*. 2015;15:82.
24. Kim JH, Kim JW, Lee TG, Lew YJ. Treatment outcomes in eyes with polypoidal choroidal vasculopathy with poor baseline visual acuity. *J Ocul Pharmacol Ther*. 2015;31(4):241-247.
25. Oishi A. The evidence for the treatment of polypoidal choroidal vasculopathy. *Nippon Ganka Gakkai Zasshi*. 2015;119(11):781-786.
26. Chang YS, Kim JH, Kim KM, et al. Long-term outcomes of anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. *J Ocul Pharmacol Ther*. 2016;32(4):219-224.
27. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 5.2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed November 11, 2024.
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version 4.2024. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed November 11, 2024.
29. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed November 11, 2024.
30. Lexicomp [database online]. Hudson, OH: Lexi-Comp, Inc.; <https://online.lexi.com/lco/action/home> [available with subscription]. Accessed February 19, 2025.
31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma Version 3.2024. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed November 19, 2024.
32. Jobevne [package insert]. Cambridge, MA: Biocon Biologics Inc.; April 2025.

SECTION 3

1. National Comprehensive Cancer Network. *About NCCN*. Available at: <https://www.nccn.org/home/about>. Accessed September 10, 2025.
2. National Comprehensive Cancer Network. *NCCN Guidelines*. Available at: https://www.nccn.org/guidelines/category_1. Accessed September 10, 2025. (Note: An account may be required.)
3. National Comprehensive Cancer Network. *NCCN Drugs and Biologics Compendium*. Available at: <https://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia>. Accessed September 10, 2025. (Note: A subscription may be required.)
4. National Comprehensive Cancer Network. *NCCN Categories of Evidence and Consensus*. Available at: <https://www.nccn.org/guidelines/guidelines-process/development-and-update-of-guidelines>. Accessed September 10, 2025.